Circ-ZEB1.33 promotes the proliferation of human HCC by sponging miR-200a-3p and upregulating CDK6
暂无分享,去创建一个
Di Wu | Yuhua Gong | Xuemei Wang | Liang Zhu | Yuhua Gong | Jinzhong Mao | Xuemei Wang | Long Li | Liang Zhu | Rong Song | Di Wu | Jin-He Mao | Rongbo Song | Long Li
[1] Lei Wang,et al. Phosphodiesterase 3/4 Inhibitor Zardaverine Exhibits Potent and Selective Antitumor Activity against Hepatocellular Carcinoma Both In Vitro and In Vivo Independently of Phosphodiesterase Inhibition , 2014, PloS one.
[2] F. Bauzon,et al. Racing to block tumorigenesis after pRb loss: An innocuous point mutation wins with synthetic lethality , 2010, Cell Cycle.
[3] Shuwen Han,et al. Competitive endogenous RNA in colorectal cancer: A systematic review. , 2018, Gene.
[4] R. Finn,et al. Treating cancer with selective CDK4/6 inhibitors , 2016, Nature Reviews Clinical Oncology.
[5] C. Barnett,et al. Cyclin‐Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future , 2016, Pharmacotherapy.
[6] J. Kjems,et al. Circular RNAs in cancer: opportunities and challenges in the field , 2017, Oncogene.
[7] F. Johnson,et al. Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers? , 2017, Expert opinion on investigational drugs.
[8] Hsien-Da Huang,et al. CircNet: a database of circular RNAs derived from transcriptome sequencing data , 2015, Nucleic Acids Res..
[9] H. Burstein,et al. Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Gil,et al. Epigenetic regulation of the INK4b-ARF-INK4a locus , 2010, Epigenetics.
[11] Xi Chen,et al. Circular RNAs: clinical relevance in cancer , 2017, Oncotarget.
[12] R. Xu,et al. Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. , 2012, The American journal of pathology.
[13] K. Coulonval,et al. Rb inactivation in cell cycle and cancer: The puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase , 2010, Cell cycle.
[14] Matthew Ingham,et al. Cell-Cycle Therapeutics Come of Age. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Qiang Yu,et al. MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma. , 2017, The Journal of investigative dermatology.
[16] G. Shapiro,et al. Targeting CDK4 and CDK6: From Discovery to Therapy. , 2016, Cancer discovery.